The Application Effect of Recombinant Human Epidermal Growth Factor Derivative Eye Drops in Patients with Dry Eye after Cataract Surgery
Objective To investigate the therapeutic effect of recombinant human epidermal growth factor(rhEGF)derivative eye drops on dry eye after cataract surgery.Methods 80 patients with dry eye syndrome after cataract surgery in Zhangshu People's Hospital from October 2020 to October 2022 were included as the study subjects and divided into two groups using a random number table method.The control group(40 cases)received sodium hyaluronate eye drops,while the observation group(40 cases)received rhEGF derivative eye drops based on the control group.Compare the clinical efficacy,tear film rupture time(BUT),corneal fluorescence staining(FL)score,tear secretion test(SIt),dry eye symptom score,inflammatory factors,and adverse reactions between the two groups.Results Compared with the control group,the observation group had a higher clinical efficacy with a statistical difference(P<0.05);the observation group had higher BUT and SIt after treatment,lower FL score and dry eye symptom score,with a statistical difference(P<0.05);the observation group had lower interleukin(IL)-1β、IL-6,tumor necrosis factor-α(TNF-α),with statistical differences(P<0.05).There was no difference in adverse reactions between the two groups(P<0.05).Conclusion rhEGF derivative eye drops can effectively promote corneal healing,enhance tear film stability,reduce eye inflammation,and have fewer side effects in the treatment of dry eye after cataract surgery.It has obvious clinical application advantages and is worth promoting.
Dry eye syndromeCataractRecombinant human epidermal growth factor derivativeCorneal endothelial cell functionInflammatory factorsTear film stability
NETL
NSTL
万方数据
